Home › Acute Biphenotypic Leukemia › Michigan

Pag-aaral pangklinika para sa Acute Biphenotypic Leukemia sa Michigan

4 pag-aaral para sa Acute Biphenotypic Leukemia ang naghahanap ng mga kalahok sa mga site sa Michigan.

Mga Lungsod sa Michigan

Opisyal na teksto ng pag-aaral (English)

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

C S Mott Children's Hospital, Ann Arbor
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
Bronson Methodist Hospital, Kalamazoo

Nagre-recruitPhase 2

365 Days · Lahat ng kasarian · Na-update Okt 27, 2026 · NCT06317662

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
at 2 pa

Nagre-recruitPhase 3

365 Days – 25 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT03959085

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

C S Mott Children's Hospital, Ann Arbor
Children's Hospital of Michigan, Detroit
Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids
at 2 pa

Nagre-recruitPhase 1/2

Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

C.S. Mott Children's Hospital, Ann Arbor

Nagre-recruitPhase 1

Edad 1 hanggang 21 · Lahat ng kasarian · Na-update Dis 6, 2024 · NCT05476770

Mula sa ClinicalTrials.gov, na-kuha noong Nob 15, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.